Breast Cancer Clinical Trial
MRg-NIRS Imaging System Breast Cancer Trial
Summary
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).
Full Description
This trial is designed to determine if the MRg-NIRS system will contribute significantly to improved clinical management of women receiving breast magnetic resonance imaging (MRI) by achieving diagnostic performance comparable to or better than dynamic contrast-enhanced (DCE) breast MRI alone.
The purpose of this clinical trial is to evaluate the addition of MRg-NIRS with and without contrast in 20 women with breast cancer. The women enrolled in the trial will be those who have a newly diagnosed breast cancer.
Eligibility Criteria
Inclusion Criteria:
Females age ≥ 18 years old
Participants capable of providing written informed consent
Women with a recent diagnosis of breast cancer.
Women who are in pre-surgical planning must have an estimated tumor size of 1.5 cm or less on available imaging.
Women who are in pre-surgical planning must have had a breast biopsy at least 10 days prior to the MRg-NIRS exam.
Exclusion Criteria:
Participants with absolute or relative contraindication to MRI:
the presence of an electronic implant, such as a pacemaker
the presence of a metal implant, such as an aneurysm clip
claustrophobia
renal failure (FDA's guidance for gadolinium of a creatinine clearance less than 30 mL/1.73 m2 BSA)
Pregnant women
Breast implants
Personal history of breast cancer in the ipsilateral breast.
Prisoners
Participants with visually inadequate healing from breast biopsy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Lebanon New Hampshire, 03756, United States
How clear is this clinincal trial information?
